Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEMIS Phase 2 study of AGA2118 in postmenopausal women with low bone mineral density
2024-515610-41-00Phase 2Authorised
- Sponsor
- Angitia Biopharmaceuticals
- Start
- Sep 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial in postmenopausal osteoporosis comparing AGA2118 with Placebo to match AGA2118 (2 arms). Primary endpoint: Percent change from baseline to Month 12 in lumbar spine bone mineral density. Planned start Sep 2025; status: authorised.
02
Drugs
AGA2118
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on 2024-515610-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515610-41-00.